Please Wait
Applying Filters...
menu
    • menu
    Egis is a Hungarian generic pharma company with 110 years history. Our activities incorporate all areas of the pharma value chain.

    Virtual Booth

    Contact Supplier

    Kewpie is your partner for Sodium Hyaluronate & Hyaluronic Acid// CEP, USDMF, KDMF & JDMF registered.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2025-03-24

    Virtual Booth

    Contact Supplier

    Centrient is a leading manufacturer of Beta-Lactam Antibiotics and a provider of next-generation Statins and Antifungals.

    Virtual Booth

    Contact Supplier

    AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2025-03-17

    Virtual Booth

    Contact Supplier

    Menu

    Mebufotenin

    DEVELOPMENTS

    DIGITAL CONTENT

    PharmaCompass
    Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    GH Research Meets Primary Endpoint in Ph 2b Trial with GH001 in TRD
    GH Research Meets Primary Endpoint in Ph 2b Trial with GH001 in TRD

    03 Feb 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com//news-release/2025/02/03/3019385/0/en/GH-Research-Announces-Primary-Endpoint-Met-in-Phase-2b-Trial-with-GH001-in-TRD-Demonstrating-15-5-Point-Placebo-adjusted-MADRS-Reduction.html

    GLOBENEWSWIRE
    03 Feb 2025
    Share Share
    Beckley Psytech begins Phase IIa treatment resistant depression trial
    Beckley Psytech begins Phase IIa treatment resistant depression trial

    22 Dec 2022

    // CLINICALTRIALSARENA

    https://www.clinicaltrialsarena.com/news/beckley-psytech-depression-trial/

    CLINICALTRIALSARENA
    22 Dec 2022
    Share Share
    Beckley Psytech Launches Phase IIa Study of Lead Candidate BPL-003
    Beckley Psytech Launches Phase IIa Study of Lead Candidate BPL-003

    21 Dec 2022

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20221221005221/en

    BUSINESSWIRE
    21 Dec 2022
    Share Share